Circulating microRNAs (miRNA) in Serum of Patients With Prostate Cancer

Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL

“…In some studies, its decrease in tissue samples harvested from cancer patients, while in our study similar to those reported by Mahn et al [30] for serum samples, though not statistically significant, increased plasma miRNA levels were observed in serum samples. [31][32][33] AUCs were calculated based on ROC curves drawn using f/T PSA data obtained from PCa 1, and PCa 2 groups (0.628).…”

“…[27,28] A study performed in patients with localized, and metastatic PCa patients refractory to castration demonstrated that miR-16 expression relatively decreased in the metastatic group. [29] Mahn et al [30] compared prostate tissues, and serum samples, and could not observed any difference between miR-16 expressions in malign, and benign prostate tissues, while higher levels of miR-16 expression were detected in sera of PCa patients when compared with BPH patients, and healthy controls. Besides, levels of miR-16 expression decreased after prostatectomy relative to preoperative values.…”

“…Studies demonstrating different expression levels in tissue, and plasma samples might be the reason for different results obtained in our study, and in some literature studies. [30] In a study where miR-203 (new nomenclature: miR-203a) expressions in malign, and normal prostate tissue were compared, decrease in miR-203 expression was demonstrated in correlation with advanced PCa, and its"anti-metastatic" value was suggested. [35] Also in our study, in compliance with the literature decrease in miR-203 levels was observed.…”

Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer

“…For instance, Lodes et al found 15 miRNAs (miR-16, -92a, -103, -107, -197, -34b, -328, -485-3p, -486-5p, -92b, -574-3p, -636, -640, -766, -885-5p) overexpressed in serum from stage 3 and 4 prostate cancer patients compared with healthy controls [65]. Furthermore, Mahn et al, found miR-26a, miR-195, and let-7i to be up-regulated in patients with prostate cancer compared with patients affected by benign prostatic hyperplasia [66]. Therefore, the different expression of specific miRNAs in liquid biopsies might be useful for a correct diagnosis.…”

Circulating microRNAs: macro-utility as markers of prostate cancer?

“…Moreover, these three miRNAs were increased in samples from men with bone metastases compared with men with localized/locally advanced disease, and miR-141 could accurately distinguish between these groups (AUCZ0.755). Mahn et al (2011) conducted a similar study but profiled four different PCa-associated miRNAs: miR-26a, miR-32, miR-195, and let-7i. They found that miR-26a, miR-195, and let-7i were increased in the serum of men with localized PCa compared with men with BPH, and a signature comprising all four miRNAs effectively distinguished between these groups (AUCZ0.758).…”